antitumor immunity in urinary bladder carcinoma patients

mohamed nor aldin mahmoud sedek.

The leukocyte adherence inhibition (IAI) test since its earlyintroduction (and up till now) was applied to detect cell-mediatedimmunoreactivity related to various types of human diseases speciallycancer. Our previous studies of human urinary bladder squamous cellcarcinoma has been conducted in this issue and expanded to other tumortypes as well as shistosomases. Cancer pati ents were chosen at early stage of the di sease to getthe highest reactivity and usage of fetal calf serum (FCS) was avoidedbecause it causes nonspeci fic adherence inhi bi leukocytes. Following incubation of peripheral blood leukocytes eithercontrol subjects or carcinoma patients serum-fr-ee in percentageadherent cells was estimated and considered as control level toxicity (SqCC/UB, ofadherence.The of the tumor extracts AdnC/UBandSqCC/CX) and other extracts (NorE/UB/B2 and Shaem/SEA/83) was exa. • mined. The nontoxic concentrations (at which nonspec:ific reduction ofcell adherence was not observed) were determined and found to be of250 ug/ml for all extracts but 25 ug/ml for Shaem/SEII/83 extract. Although tumor extracts were prepared by one and the same method, different tumor-antigen preparations varied vastly in their ability togive specific adherence inhibition. All preparations consistently gavea high tumor-specific LA! (20% decreased adherence or more). Only the SqCC/UB2/82 fail ed to express such 1 evel of adherence reducti on. USE! of this extract was avoided. Peri pheral blood 1eukocyte samples from SqCC/UBpati ents showedspeci fic LAI when reacted with SqCC/UBI/80, SqCC/L;el/82 andSqCC/U83/82, while no reactivity was observed when reacted withTCC/UBI/80, NorE/UBI/82, SqCC/CX1/82 or Shaem/SEA/83 extracts. Peripheral blood leukocytes of bladder carcinomapatients, cervical carcinoma s.haematobiWII patients showed thesame way of specificity of LAI in presence of their !oensitizing antigens.Cross reactions between various types of uriOiiry bladder be combletely absent, carcinomaswas found to indicating specificity. Such absence of cross-reactivity was also demonstrated lbetween urinary bladder and cervical squamous cell carcinomas. Thi sindicated organ tissue type specificity. Shaem was also none crossreacting with SqCC/U8 which reveal ed that S. haema~obiWII (as COfIITIOIIinfection in urinary bladder carcinoma) does not tnterf'ere ••i.th cel lularimmune reactions of SqCCpatients.The SqCC/UB1/82 reactive antigen was purified by gel filtrationchromatography. The peack Creta t ned all the anti genic acti vi ty asdetected by the LAI technique at the same 250

ug/ml concentration asthe crude extract. Molecular weight of this active fraction was es ttmatedand found to be of 16,227 daltons. Two versions of the LAI assay (haemocytometer and microplate) were at the same level of sensitivity in detectins C~II in urinary bladder carcinoma patients. The tube modification of the LAI testfailed to show reliable results when tests were performed using PBMCof the same patients. The difficulties in counting, visually, the adherent cells lead to the introduction of colorimetric modifications of the micro-LAI version. Establishment of what is referred to as the TPC/microcolorimetericLAI-assay was performed. This assay showed reliable results indetecting specific adherence reduction of leukocytes. The mechanisms involved in the LAI reaction were detected by the established TPC/microcolorimetric modification of LAI assay. Nomediator of the lymphokin family could be detected. Mechanism was confirmed to be dependent on T cell s, B cell sand monocytes di recti nteraction with the sens iti zi ng anti gen, and on monocyte dependenceon B lymphocyte arming. T lymphocytes, regardless that putativemediators, are active whempresent in a pure popul ati 011 ••